Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Elenbecestat

- PMLiVE

Theranexus takes Alzheimer’s drug combo into clinic

150-subject phase 1b trial to start at eight centres in France

- PMLiVE

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Surprise findings from primate studies

EISAI

Eisai’s Lenvima wins European liver cancer indication

EC green-lights the RTK inhibitor as a first-line treatment

- PMLiVE

Shock as NICE turns down Biogen’s SMA therapy

UK’s cost effectiveness watchdog says the drug’s long-term benefits are unclear

Biogen Idec building

Big debate follows Biogen/Eisai’s Alzheimer’s study unveiling

Mixed results prompted a 10% share drop for both companies

- PMLiVE

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Biotech sees 9% growth ahead of potential landmark announcement

- PMLiVE

Daily Brief: Janssen’s HIV vaccine, Q2 results, Biogen’s Alzheimer’s data

News from pharma, biotech and healthcare

Biogen Idec building

Biogen and Eisai claim mid-stage win for Alzheimer’s drug

Says drug slowed down progression of cognitive decline

- PMLiVE

Anavex sets up trial of ‘triple-action’ Alzheimer’s drug

US biotech's novel drug is latest to join war on Alzheimer's

- PMLiVE

Eisai to tackle dementia in new US research facility

Aims to introduce a new compound into the clinic by 2020

- PMLiVE

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

Another BACE candidate is abandoned, leaving just one remaining in the pipeline

- PMLiVE

Biogen appoints executive VP, corporate development

Daniel Karp will also become a member of the executive committee

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links